Journal of Bone and Mineral Metabolism

, Volume 31, Issue 4, pp 367–380 | Cite as

Osteoporosis and treatments in Japan: management for preventing subsequent fractures

  • Shuko Nojiri
  • Russel T. Burge
  • Jennifer A. Flynn
  • Shonda A. Foster
  • Hideaki Sowa
Review Article

Abstract

Prevalent fractures are major contributors to an increased risk of subsequent fractures, particularly in people with osteoporosis. While many studies have been conducted to assess the incidence of fracture in Japanese people with osteoporosis, far fewer have been conducted to assess the risk of subsequent fractures. This article reviews the morbidity, mortality, and risk of fracture in patients who are at high risk of subsequent fracture in Japan and the current treatment options available for these patients. Osteoporotic fractures in Japan are associated with high morbidity and mortality that result in significant financial and social costs. The rise in the proportion of elderly women in the Japanese population is contributing to a greater proportion of people with osteoporotic fractures and the high cost of osteoporosis. Although hip fractures have a significant effect on costs, a greater proportion of the Japanese population experience vertebral fractures. An increase in the incidence of vertebral fractures is concerning because preexisting vertebral fractures in older patients are associated with an increased risk of subsequent fractures. Hence, there is a clear rationale for pharmacological treatment of patients with prevalent vertebral fractures, or for those who are hospitalized or undergo surgery for osteoporotic fractures. Several pharmacological therapies are now available in Japan for the treatment of patients with osteoporosis. Understanding the consequences of subsequent fractures and the treatment options available for patients at high risk of subsequent fractures may contribute to clinical decision-making and improved outcomes for patients with osteoporosis.

Keywords

Drug therapy Fracture risk Japan Osteoporosis 

References

  1. 1.
    Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897–902PubMedCrossRefGoogle Scholar
  2. 2.
    Hagino H, Furukawa K, Fujiwara S, Okano T, Katagiri H, Yamamoto K, Teshima R (2009) Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int 20:543–548PubMedCrossRefGoogle Scholar
  3. 3.
    Morita Y, Endo N, Iga T, Tokunaga K, Ohkawa Y (2002) The incidence of cervical and trochanteric fractures of the proximal femur in 1999 in Niigata Prefecture, Japan. J Bone Miner Metab 20:311–318PubMedCrossRefGoogle Scholar
  4. 4.
    Oinuma T, Sakuma M, Endo N (2010) Secular change of the incidence of four fracture types associated with senile osteoporosis in Sado, Japan: the results of a 3-year survey. J Bone Miner Metab 28:55–59PubMedCrossRefGoogle Scholar
  5. 5.
    Orimo H, Yaegashi Y, Onoda T, Fukushima Y, Hosoi T, Sakata K (2009) Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos 4:71–77PubMedCrossRefGoogle Scholar
  6. 6.
    Christensen K, Doblhammer G, Rau R, Vaupel JW (2009) Ageing populations: the challenges ahead. Lancet 374:1196–1208PubMedCrossRefGoogle Scholar
  7. 7.
    World Health Organization (2004) WHO Scientific Group on the assessment of osteoporosis at primary health care level: summary meeting report. Brussels, Belgium; 5–7 MayGoogle Scholar
  8. 8.
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRefGoogle Scholar
  9. 9.
    Yamaguchi T, Sugimoto T (2011) Bone metabolism and fracture risk in type 2 diabetes mellitus. Endocr J 58:613–624PubMedCrossRefGoogle Scholar
  10. 10.
    Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32:78–85PubMedCrossRefGoogle Scholar
  11. 11.
    (2006) Japanese Guidelines for the Prevention and Treatment of Osteoporosis (in Japanese). Life Science Publishing Co. Ltd, TokyoGoogle Scholar
  12. 12.
    Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27:620–628PubMedCrossRefGoogle Scholar
  13. 13.
    Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547–1553PubMedCrossRefGoogle Scholar
  14. 14.
    Iwamoto J, Sato Y, Takeda T, Matsumoto H (2012) Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature. Drugs Aging 29:191–203PubMedCrossRefGoogle Scholar
  15. 15.
    Statistics Bureau (2011) Population Estimates (1920–2000). Ministry of Internal Affairs and Communications, Tokyo. Available from: http://www.e-stat.go.jp/SG1/estat/ListE.do?bid=000000090004&cycode=0
  16. 16.
    Statistics Bureau (2011) Current Population Estimates, Annual Reports 2001–2009. Ministry of Internal Affairs and Communications, Tokyo. Available from: http://www.stat.go.jp/english/data/jinsui/2.htm
  17. 17.
    Statistics Bureau (2011) Population Estimates (September 2011). Ministry of Internal Affairs and Communications, Tokyo. Available from: http://www.stat.go.jp/english/data/jinsui/tsuki/index.htm
  18. 18.
    US Census Bureau (2011) International Programs: International Data Base, Japan. Available from: http://www.census.gov/population/international/data/idb/country.php
  19. 19.
    Kimura A (2004) The medical economic problem of the cost with the treatment for the fractures based on osteoporosis (in Japanese). Clin Calcium 14:371–376PubMedGoogle Scholar
  20. 20.
    Ministry of Health Labour and Welfare (2010) National Livelihood Survey (in Japanese). Tokyo, Japan; [cited October 2011]; Available from: http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa10/4-2.html
  21. 21.
    Sakuma M, Endo N, Oinuma T, Endo E, Yazawa T, Watanabe K, Watanabe S (2008) Incidence and outcome of osteoporotic fractures in 2004 in Sado City, Niigata Prefecture, Japan. J Bone Miner Metab 26:373–378PubMedCrossRefGoogle Scholar
  22. 22.
    Ding H, Koinuma N, Stevenson M, Ito M, Monma Y (2008) The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis. J Bone Miner Metab 26:34–41PubMedCrossRefGoogle Scholar
  23. 23.
    Ogawa K, Fujino S (1996) Estimates of cost-of-illness of osteoporosis in Japan (1992) (in Japanese). J Health Care Soc 6:1–15Google Scholar
  24. 24.
    Shiraki M, Kuroda T, Tanaka S (2011) Established osteoporosis associated with high mortality after adjustment for age and co-morbidities in postmenopausal Japanese women. Intern Med 50:397–404PubMedCrossRefGoogle Scholar
  25. 25.
    Suzuki T, Yoshida H (2010) Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women. Osteoporos Int 21:71–79PubMedCrossRefGoogle Scholar
  26. 26.
    Kuroda T, Shiraki M, Tanaka S, Ohta H (2009) Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. Bone 44:168–172PubMedCrossRefGoogle Scholar
  27. 27.
    Ishikawa M, Kazutoshi N, Tamura T, Akiyama S, Tsuchiya Y (2006) Ethnic differences between Asians and Caucasians in the incidence of osteoporotic fractures: a review. Acta Med Biol 54:63–66Google Scholar
  28. 28.
    Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton LJ 3rd (1995) Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24:1171–1177PubMedCrossRefGoogle Scholar
  29. 29.
    Kin K, Lee JH, Kushida K, Sartoris DJ, Ohmura A, Clopton PL, Inoue T (1993) Bone density and body composition on the Pacific rim: a comparison between Japan-born and U.S.-born Japanese-American women. J Bone Miner Res 8:861–869PubMedCrossRefGoogle Scholar
  30. 30.
    Miyakoshi N, Hongo M, Maekawa S, Ishikawa Y, Shimada Y, Itoi E (2007) Back extensor strength and lumbar spinal mobility are predictors of quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 18:1397–1403PubMedCrossRefGoogle Scholar
  31. 31.
    Miyakoshi N, Itoi E, Kobayashi M, Kodama H (2003) Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis. Osteoporos Int 14:1007–1012PubMedCrossRefGoogle Scholar
  32. 32.
    Jinbayashi H, Aoyagi K, Ross PD, Ito M, Shindo H, Takemoto T (2002) Prevalence of vertebral deformity and its associations with physical impairment among Japanese women: the Hizen-Oshima Study. Osteoporos Int 13:723–730PubMedCrossRefGoogle Scholar
  33. 33.
    Ikeda Y, Sudo A, Yamada T, Uchida A (2010) Mortality after vertebral fractures in a Japanese population. J Orthop Surg (Hong Kong) 18:148–152Google Scholar
  34. 34.
    Arakaki H, Owan I, Kudoh H, Horizono H, Arakaki K, Ikema Y, Shinjo H, Hayashi K, Kanaya F (2011) Epidemiology of hip fractures in Okinawa, Japan. J Bone Miner Metab 29:309–314PubMedCrossRefGoogle Scholar
  35. 35.
    Japanese Osteoporosis Society Symposium (2010) Prevention of osteoporosis and treatment guideline update (in Japanese). Osteoporos Jpn 18:5–8Google Scholar
  36. 36.
    Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244PubMedCrossRefGoogle Scholar
  37. 37.
    Ishii S, Cauley JA, Greendale GA, Danielson ME, Safaei Nili N, Karlamangla A (2012) Ethnic differences in composite indices of femoral neck strength. Osteoporos Int 23:1381–1390PubMedCrossRefGoogle Scholar
  38. 38.
    Hagino H, Sakamoto K, Harada A, Nakamura T, Mutoh Y, Mori S, Endo N, Nakano T, Itoi E, Kita K, Yamamoto N, Aoyagi K, Yamazaki K (2010) Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci 15:737–745PubMedCrossRefGoogle Scholar
  39. 39.
    Sakamoto K, Nakamura T, Hagino H, Endo N, Mori S, Muto Y, Harada A, Nakano T, Yamamoto S, Kushida K, Tomita K, Yoshimura M, Yamamoto H (2006) Report on the Japanese Orthopaedic Association’s 3-year project observing hip fractures at fixed-point hospitals. J Orthop Sci 11:127–134PubMedCrossRefGoogle Scholar
  40. 40.
    Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702PubMedCrossRefGoogle Scholar
  41. 41.
    Kondo A, Zierler BK, Isokawa Y, Hagino H, Ito Y, Richerson M (2010) Comparison of lengths of hospital stay after surgery and mortality in elderly hip fracture patients between Japan and the United States - the relationship between the lengths of hospital stay after surgery and mortality. Disabil Rehabil 32:826–835PubMedCrossRefGoogle Scholar
  42. 42.
    Gehlbach SH, Avrunin JS, Puleo E (2007) Trends in hospital care for hip fractures. Osteoporos Int 18:585–591PubMedCrossRefGoogle Scholar
  43. 43.
    Kondo A, Zierler BK, Hagino H (2010) Relationship between the length of hospital stay after hip fracture surgery and ambulatory ability or mortality after discharge in Japan. Jpn J Nurs Sci 7:96–107PubMedCrossRefGoogle Scholar
  44. 44.
    Suzuki T, Yoshida H, Ishizaki T (1998) Epidemiology of osteoporosis: incidence, prevalence, and prognosis (in Japanese). Nihon Rinsho 56:1563–1568PubMedGoogle Scholar
  45. 45.
    Muraki S, Yamamoto S, Ishibashi H, Nakamura K (2006) Factors associated with mortality following hip fracture in Japan. J Bone Miner Metab 24:100–104PubMedCrossRefGoogle Scholar
  46. 46.
    Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
  47. 47.
    Fujiwara S, Kasagi F, Yamada M, Kodama K (1997) Risk factors for hip fracture in a Japanese cohort. J Bone Miner Res 12:998–1004PubMedCrossRefGoogle Scholar
  48. 48.
    Tanaka S, Yoshimura N, Kuroda T, Hosoi T, Saito M, Shiraki M (2010) The Fracture and Immobilization Score (FRISC) for risk assessment of osteoporotic fracture and immobilization in postmenopausal women-a joint analysis of the Nagano, Miyama, and Taiji Cohorts. Bone 47:1064–1070PubMedCrossRefGoogle Scholar
  49. 49.
    Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14–21PubMedCrossRefGoogle Scholar
  50. 50.
    Kadowaki E, Tamaki J, Iki M, Sato Y, Chiba Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H (2010) Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 21:1513–1522PubMedCrossRefGoogle Scholar
  51. 51.
    Nakamura K, Oyama M, Takahashi S, Yoshizawa Y, Kobayashi R, Oshiki R, Saito T, Tsuchiya Y (2010) Fracture incidence in nursing homes in Japan. Osteoporos Int 21:797–803PubMedCrossRefGoogle Scholar
  52. 52.
    Mitani S, Shimizu M, Abo M, Hagino H, Kurozawa Y (2010) Risk factors for second hip fractures among elderly patients. J Orthop Sci 15:192–197PubMedCrossRefGoogle Scholar
  53. 53.
    Yamanashi A, Yamazaki K, Kanamori M, Mochizuki K, Okamoto S, Koide Y, Kin K, Nagano A (2005) Assessment of risk factors for second hip fractures in Japanese elderly. Osteoporos Int 16:1239–1246PubMedCrossRefGoogle Scholar
  54. 54.
    Fujiwara S, Hamaya E, Goto W, Masunari N, Furukawa K, Fukunaga M, Nakamura T, Miyauchi A, Chen P (2011) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan. Bone 49:520–525PubMedCrossRefGoogle Scholar
  55. 55.
    Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986–995PubMedCrossRefGoogle Scholar
  56. 56.
    Nampei A, Hashimoto J, Koyanagi J, Ono T, Hashimoto H, Tsumaki N, Tomita T, Sugamoto K, Nishimoto N, Ochi T, Yoshikawa H (2008) Characteristics of fracture and related factors in patients with rheumatoid arthritis. Mod Rheumatol 18:170–176PubMedCrossRefGoogle Scholar
  57. 57.
    Koike T, Orito Y, Toyoda H, Tada M, Sugama R, Hoshino M, Nakao Y, Kobayashi S, Kondo K, Hirota Y, Takaoka K (2009) External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporos Int 20:1613–1620PubMedCrossRefGoogle Scholar
  58. 58.
    Harada A, Matsui Y, Mizuno M, Tokuda H, Niino N, Ohta T (2004) Japanese orthopedists’ interests in prevention of fractures in the elderly from falls. Osteoporos Int 15:560–566PubMedCrossRefGoogle Scholar
  59. 59.
    Iba K, Takada J, Hatakeyama N, Kaya M, Isogai S, Tsuda H, Obata H, Miyano S, Yamashita T (2006) Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture. J Orthop Sci 11:446–449PubMedCrossRefGoogle Scholar
  60. 60.
    Furuya T, Hosoi T, Saito S, Inoue E, Taniguchi A, Momohara S, Yamanaka H (2011) Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis. Clin Rheumatol 30:1105–1111PubMedCrossRefGoogle Scholar
  61. 61.
    Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA (2002) Hip fracture patients are not treated for osteoporosis: a call to action. Arthr Rheum 47:651–654CrossRefGoogle Scholar
  62. 62.
    Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052–2057PubMedCrossRefGoogle Scholar
  63. 63.
    Petrella RJ, Jones TJ (2006) Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam Pract 7:31PubMedCrossRefGoogle Scholar
  64. 64.
    Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA et al (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49:493–498PubMedCrossRefGoogle Scholar
  65. 65.
    (2013) Bonalon®: alendronate sodium hydrate [package insert]. Teijin Ltd, TokyoGoogle Scholar
  66. 66.
    (2013) Fosamax®: alendronate sodium hydrate [package insert]. MSD, TokyoGoogle Scholar
  67. 67.
    (2012) Teiroc®: alendronate sodium hydrate [package insert]. Teijin Ltd, TokyoGoogle Scholar
  68. 68.
    (2012) Didronel®: etidronate disodium [package insert]. Dainippon Sumitomo Pharma Ltd, OsakaGoogle Scholar
  69. 69.
    (2012) Actonel®: risendronate sodium hydrate [package insert]. Co. Inc./Eisai Pharmaceutical Co. Ltd, TokyoGoogle Scholar
  70. 70.
    (2012) Benet®: risendronate sodium hydrate [package insert]. Takeda Pharmaceutical Co. Ltd, OsakaGoogle Scholar
  71. 71.
    (2013) Evista®: raloxifene hydrochloride [package insert]. Eli Lilly Japan K.K., KobeGoogle Scholar
  72. 72.
    (2011) Alfarol®: alfacalcidol [package insert]. Chugai Pharmaceutical Co. Ltd, TokyoGoogle Scholar
  73. 73.
    (2011) One-Alfa®: alfacalcidol [package insert]. Teijin Ltd, TokyoGoogle Scholar
  74. 74.
    (2012) Eldirol®: eldecalcitol [package insert]. Chugai Pharmaceutical Co. Ltd, TokyoGoogle Scholar
  75. 75.
    (2012) Bonoteo®: minodronic acid hydrate [package insert]. Astellas Pharma Inc, TokyoGoogle Scholar
  76. 76.
    (2012) Recalbon®: minodronic acid hydrate [package insert]. Ono pharmaceutical Co. Ltd, OsakaGoogle Scholar
  77. 77.
    (2011) Viviant®: Bazedoxifene acetate [package insert]. Pfizer Co. Ltd, TokyoGoogle Scholar
  78. 78.
    (2011) Forteo® [prescribing information]. Eli Lilly Japan K.K., KobeGoogle Scholar
  79. 79.
    Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65–74PubMedCrossRefGoogle Scholar
  80. 80.
    Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H (2008) Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J 49:119–128PubMedCrossRefGoogle Scholar
  81. 81.
    Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)-02. Curr Med Res Opin 27:1273–1284PubMedCrossRefGoogle Scholar
  82. 82.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971–979PubMedCrossRefGoogle Scholar
  83. 83.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084PubMedCrossRefGoogle Scholar
  84. 84.
    Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469–478PubMedGoogle Scholar
  85. 85.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437PubMedCrossRefGoogle Scholar
  86. 86.
    Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRefGoogle Scholar
  87. 87.
    Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence–a multi-centre study. J Craniomaxillofac Surg 39:272–277PubMedCrossRefGoogle Scholar
  88. 88.
    Seeman E (2009) To stop or not to stop, that is the question. Osteoporos Int 20:187–195PubMedCrossRefGoogle Scholar
  89. 89.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRefGoogle Scholar
  90. 90.
    Dutertre M, Smith CL (2000) Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295:431–437PubMedGoogle Scholar
  91. 91.
    Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793–800PubMedCrossRefGoogle Scholar
  92. 92.
    Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, Mulitple Outcomes of Raloxifene Evaluation Investigators (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617PubMedCrossRefGoogle Scholar
  93. 93.
    Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313–316PubMedCrossRefGoogle Scholar
  94. 94.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista Investigators (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514–1524PubMedCrossRefGoogle Scholar
  95. 95.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMedCrossRefGoogle Scholar
  96. 96.
    Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535PubMedCrossRefGoogle Scholar
  97. 97.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934PubMedCrossRefGoogle Scholar
  98. 98.
    Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H, Gorai I, Sugimoto T, Mizunuma H, Ochi H, Constantine GD, Ohta H (2011) Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 26:519–529PubMedCrossRefGoogle Scholar
  99. 99.
    Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S, Multiple Outcomes of Raloxifene Evaluation I (2004) Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104:837–844PubMedCrossRefGoogle Scholar
  100. 100.
    Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40:1447–1452PubMedCrossRefGoogle Scholar
  101. 101.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRefGoogle Scholar
  102. 102.
    Prevrhal S, Krege JH, Chen P, Genant H, Black DM (2009) Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25:921–928PubMedCrossRefGoogle Scholar
  103. 103.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513PubMedCrossRefGoogle Scholar
  104. 104.
    Ryder KM, Tanner SB, Carbone L, Williams JE, Taylor HM, Bush A, Pintea V, Watsky MA (2010) Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J Bone Miner Metab 28:233–239PubMedCrossRefGoogle Scholar
  105. 105.
    Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502PubMedCrossRefGoogle Scholar
  106. 106.
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321PubMedCrossRefGoogle Scholar
  107. 107.
    Center for Drug Evaluation and Research (2012) Endocrinologic and Metabolic Drugs Advisory Committee, Food and Drug Administration. Available from: http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3761t2_01.pdf
  108. 108.
    Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429–2437PubMedCrossRefGoogle Scholar
  109. 109.
    Harper KD, Krege JH, Marcus R, Mitlak BH (2007) Osteosarcoma and teriparatide? J Bone Miner Res 22:334PubMedCrossRefGoogle Scholar
  110. 110.
    Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041–1045PubMedCrossRefGoogle Scholar
  111. 111.
    Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C (2010) Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab 28:68–76PubMedCrossRefGoogle Scholar
  112. 112.
    Nakamura K, Saito T, Oyama M, Oshiki R, Kobayashi R, Nishiwaki T, Nashimoto M, Tsuchiya Y (2011) Vitamin D sufficiency is associated with low incidence of limb and vertebral fractures in community-dwelling elderly Japanese women: the Muramatsu Study. Osteoporos Int 22:97–103PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2013

Authors and Affiliations

  • Shuko Nojiri
    • 1
  • Russel T. Burge
    • 2
  • Jennifer A. Flynn
    • 1
  • Shonda A. Foster
    • 2
  • Hideaki Sowa
    • 3
  1. 1.Japan Health Technology AssessmentEli Lilly Japan K.K.KobeJapan
  2. 2.Global Health OutcomesEli Lilly and CompanyIndianapolisUSA
  3. 3.Medical ScienceEli Lilly Japan K.K.KobeJapan

Personalised recommendations